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Background. The impact of human immunodeficiency virus (HIV) infection on influenza incidence and severity in adults in 
sub-Saharan Africa is unclear. Seasonal influenza vaccination is recommended for HIV-infected persons in developed settings but 
is rarely implemented in Africa.
Methods. We conducted a prospective cohort study to compare the incidence of laboratory-confirmed influenza illness between 
HIV-infected and HIV-uninfected adults in Blantyre, Malawi. In a parallel case-control study, we explored risk factors for severe 
influenza presentation of severe (hospitalized) lower respiratory tract infection, and mild influenza (influenza-like illness [ILI]).
Results. The cohort study enrolled 608 adults, of whom 360 (59%) were HIV infected. Between April 2013 and March 2015, 24 
of 229 ILI episodes (10.5%) in HIV-infected and 5 of 119 (4.2%) in HIV-uninfected adults were positive for influenza by means of 
polymerase chain reaction (incidence rate, 46.0 vs 14.5 per 1000 person-years; incidence rate ratio, 2.75; 95% confidence interval, 
1.02–7.44; P = .03; adjusted for age, sex, household crowding, and food security). In the case-control study, influenza was identified 
in 56 of 518 patients (10.8%) with hospitalized lower respiratory tract infection, and 88 or 642 (13.7%) with ILI. The HIV prevalence 
was 69.6% and 29.6%, respectively, among influenza-positive case patients and controls. HIV was a significant risk factor for severe 
influenza (odds ratio, 4.98; 95% confidence interval, 2.09–11.88; P < .001; population-attributable fraction, 57%; adjusted for season, 
sanitation facility, and food security).
Conclusions. HIV is an important risk factor for influenza-associated ILI and severe presentation in this high–HIV prevalence 
African setting. Targeted influenza vaccination of HIV-infected African adults should be reevaluated, and the optimal mechanism 
for vaccine introduction in overstretched health systems needs to be determined.
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Influenza and its complications are leading causes of disease and 
death worldwide [1]. Vaccination of patient groups at increased 
risk of influenza-related complications is key to minimizing the 
impact of disease. Influenza vaccines are currently unavailable 
in the public sector in most sub-Saharan African countries [2]. 
The World Health Organization has therefore called for more 
data on influenza disease burden in the region to guide influ-
enza prevention and control programs [3].
Persons with human immunodeficiency virus (HIV) infec-
tion are designated a priority for immunization in many 
well-resourced countries [4, 5], but data to support this rec-
ommendation are inconsistent. HIV does not significantly 
increase influenza burden or severity in developed settings [6, 
7]. Conversely, in low-resource settings with high HIV prev-
alence there is a higher incidence of influenza illness [8–10] 
and a greater risk of hospitalization [11–13] and death among 
HIV-infected persons [9, 14, 15]. Current studies, however, 
are limited by incomplete ascertainment of HIV status, CD4+ 
cell counts, and antiretroviral treatment (ART), and few have 
studied the impact of environmental factors, such as house-
hold crowding and sanitation. We therefore aimed to deter-
mine the impact of HIV on the frequency and severity of adult 
laboratory-confirmed influenza illness in an urban, high–HIV 
prevalence African setting, and identify additional risk factors 
associated with influenza illness and severity.
METHODS
Study Setting and Design
Malawi is a low-income Southern African country, with an HIV 
prevalence of 10.6% [16]. Influenza predominantly circulates 
M A J O R  A R T I C L E
© The Author(s) 2017. Published by Oxford University Press for the Infectious Diseases 
Society of America. This is an Open Access article distributed under the terms of the Creative 
Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits 
unrestricted reuse, distribution, and reproduction in any medium, provided the original work 
is properly cited.
DOI: 10.1093/cid/cix903
Received 27 June 2017; editorial decision 2 October 2017; accepted 14 October 2017.
aR. S. H. and N. F. contributed equally to this work.
Correspondence: A. Ho, Institute of Infection and Global Health, University of Liverpool, 
Liverpool, L69 7BE, United Kingdom (toniho@doctors.org.uk).
Clinical Infectious Diseases®  2017;XX(00):1–12
Downloaded from https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/cix903/4554430
by University of Glasgow user
on 20 February 2018
2 • CID 2017:XX (XX XXXX) • Ho et al
between January and April [17]. There is no national influenza 
immunization program. We performed 2 prospective observa-
tional studies at the Queen Elizabeth Central Hospital (QECH), 
the only inpatient facility providing free healthcare to 1.3 mil-
lion residents in Blantyre district, and a primary care center 
adjacent to QECH.
We conducted a cohort study of HIV-infected and HIV-
uninfected adults over 2  years; the primary end point was 
laboratory-confirmed influenza illness. We also performed a 
case-control study in adults presenting with mild and severe in-
fluenza, to establish risk factors for severe influenza (including 
HIV infection).
PROCEDURES
Cohort Study
We enrolled adults (aged ≥18 years) from the ART and volun-
tary counseling and testing clinics at QECH beginning 1 April 
2013 (eligibility criteria shown in Figure 1). Active follow-up 
comprised bimonthly routine clinic reviews. Participants were 
also instructed to attend the study clinic when they experi-
ence an influenza-like illness (ILI), defined as reported or 
documented fever (≥38°C) and ≥2 of the following symptoms: 
cough, rhinorrhea, sore throat, myalgia, headache, and vomit-
ing/diarrhea. The study clinician assessed ill participants and 
instituted appropriate management. Paired nasopharyngeal and 
oropharyngeal swab samples (FLOQswabs; Copan Diagnostics) 
were obtained at routine and ILI visits [18].
We compared the incidence of laboratory-confirmed influ-
enza-associated ILI between HIV-infected and HIV-uninfected 
participants. The at-risk period was calculated from enroll-
ment to the study end date (31 March 2015), death, or loss to 
follow-up. For participants lost to follow-up, follow-up was 
censored on the date of relocation, withdrawal of consent, or 
the last recorded clinic visit.
Case-Control Study
Between 15 May 2013 and 28 February 2015, we recruited adults 
admitted to QECH with acute lower respiratory tract infection 
(LRTI) (severe cases) and adults attending the primary care 
center with ILI (nonsevere disease) (eligibility criteria shown 
in Figure  2). Nasopharyngeal aspirate samples were obtained 
at enrollment. Participants with influenza-positive hospitalized 
LRTI and outpatient-managed ILI made up the case patients 
and controls, respectively.
Laboratory Procedures
Laboratory testing was performed at the Malawi–Liverpool–
Wellcome Trust Clinical Research Programme laboratory. HIV 
status was established by means of sequential rapid HIV tests 
(Alere Determine and Uni-Gold, Trinity Biotech) [19]. CD4+ 
cell counts were performed using a FACScount flow cytom-
eter (Becton Dickinson; BD Biosciences). Nasopharyngeal 
specimens were tested for influenza A and B viruses using the 
Centers for Disease Control and Prevention human influenza 
quantitative reverse-transcription polymerase chain reaction 
(PCR) diagnostic panel and influenza A subtyping kit [20].
Statistical Analysis
Analysis was performed with Stata software (version 12.1). We 
tested differences in categorical variables using χ2 or Fisher 
exact test, and differences in continuous variables using t or 
Wilcoxon rank sum test, as appropriate. The cohort study was 
powered to detect an incidence rate ratio (IRR) of ≥3.0 (α = .05; 
2-tailed β  =  .2), for influenza-associated ILI by HIV status, 
requiring 608 recruits and allowing for 20% loss-to follow-up, 
Figure 1. Eligibility criteria for cohort study. Abbreviations: HIV, human immunodeficiency virus; QECH, Queen Elizabeth Central Hospital.
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based on an estimated cumulative incidence of 40 per 1000 per-
son-years [PY] in the HIV-uninfected cohort and a 60:40 ratio 
of HIV infection to noninfection.
Incidence rates of influenza-associated ILI were calculated by 
dividing the number of events by the number of person-years 
of follow-up. Poisson regression models were used to estimate 
IRRs and 95% confidence intervals (CIs) for the effect of HIV 
and other risk factors on influenza. Age, sex, and HIV infection 
were included as potential confounders in the multivariable 
models. Population average Poisson regression models using 
generalized estimating equations were constructed for recur-
rent events.
In both studies, stepwise backward elimination of covariates 
with P values < .20 was used to rationalize the multivariable 
models. We limited the number of covariates in a multivariable 
model to maintain a limit of 10 events per variable [21]. Two-
way interactions were evaluated in all final models. All available 
case information was used in each univariable analysis. In the 
multivariable models, we excluded patients with missing data 
for included variables (data were >95% complete for all varia-
bles). The impact of ART and CD4+ cell count was assessed in 
subgroup analyses of HIV-infected individuals.
For the case-control study, a sample size of 57 case patients 
and 114 unmatched controls provided 80% power to detect an 
odds ratio (OR) of ≥2.5. Based on observed influenza preva-
lences of 11% and 16.4% in adults presenting to QECH with 
severe or mild acute respiratory illness, respectively, in our sen-
tinel surveillance (unpublished data), we estimated recruitment 
of approximately 518 adults with hospitalized LRTI and 695 
adults with ILI.
We estimated the OR of having HIV infection and other 
potential risk factors for severe influenza in case patients 
and controls, controlling for confounders, using uncondi-
tional logistic regression models. HIV status and recruit-
ment season were included a priori in the multivariable 
model. Population-attributable fractions of modifiable risk 
factors for severe influenza were estimated from the prev-
alence of exposure in case patients and adjusted OR from 
Reported fever OR recorded fever (≥38°C)
Inclusion criteria
Inclusion criteria
Hospitalized LRTI (case patients)
ILI (controls)
Exclusion criteria
Exclusion criteria
Reported fever OR recorded fever (≥38°C)
Symptoms for ≤7 d
Not requiring hospitalization for ILI presentation
Preadmission diagnosis of terminal illness (eg, metastatic cancer)
Current antituberculous treatment
Prior hospitalization within last 4 wk
Suspected concurrent meningitis
Prior participation in the study
≥2 of the following: cough, sore throat, rhinorrhea, myalgia, vomiting/diarrhea OR
headache
Reported cough OR chest pain OR breathlessness OR hemoptysis
Crepitations OR pleural rub OR bronchial breathing OR signs suggestive of pleural
effusion on clinical examination
Require hospitalization
Preadmission diagnosis of terminal illness (eg, metastatic cancer)
Current antituberculous treatment
Admission to hospital >24 h before recruitment
Symptoms for ≥14 d
Prior hospitalization within last 4 wk
Suspected concurrent meningitis
Prior participation in the study
Figure 2. Eligibility criteria for case-control study. Abbreviations: ILI, influenzalike illness; LRTI, lower respiratory tract infection.
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the multivariable logistic regression model [22]. Ethical 
approval was provided by the University of Malawi College 
of Medicine Research Ethics Committee (Study No. 
P.11/12/1310) and the Research Ethics Committee of the 
University of Liverpool (Study No. 12.43).
RESULTS
Cohort Study: Participant Characteristics
In total, 608 adults were enrolled; 360 (59%) had HIV infection 
(Figure 3 and Table 1). Compared with HIV-uninfected partic-
ipants, HIV-infected participants were older (median age, 37 vs 
31 years; P < .001), and a higher proportion were female (69% 
vs 55%; P = .001). Chronic lung disease and smoking were un-
common in both groups. A significantly higher proportion of 
HIV-infected participants reported previous tuberculosis (25% 
vs 2%; P < .001) and pneumonia in the past 5 years (16% vs 5%; 
P < .001).
HIV-uninfected participants had larger households, but 
crowding was similar in the 2 groups. HIV-uninfected partic-
ipants had better sanitation facilities, water supply, and food 
security. No significant differences were observed in education 
level, employment, or asset ownership.
Of the 360 HIV-infected participants, 234 (65.0%) were 
receiving ART at enrolment, the majority (82%) for >12 months. 
The median CD4+ cell count at enrollment was 390/µL (inter-
quartile range, 244–547/µL).
Eleven participants died during the study (HIV infected, 
n = 10); none had reported respiratory symptoms before death. 
Sixty-one participants (10%) migrated out of Blantyre, 24 
(3.9%) withdrew consent, and 25 (4.1%) were lost to follow-up 
(Figure 3). There was no differential loss to follow-up by HIV 
status. The total person-time follow-up was 520 and 348 PY in 
the HIV-infected and HIV-uninfected cohorts, respectively.
Impact of HIV Infection on Influenza-Associated ILI Incidence
We recorded 348 ILI episodes in 208 participants (HIV infected, 
n = 130) (clinical characteristics show in Supplementary Table 
S1). The incidences of ILI presentation were 442 and 341 per 
1000 PY in the HIV-infected and HIV-uninfected participants, 
respectively (IRR, 1.21; 95% CI, .99–1.48). Twenty-nine ILI 
episodes (8.3%) had PCR results positive for influenza, includ-
ing influenza A(H3N2) (n = 11) and influenza B (n = 18) and 
occurring in 24 (10.5%) of 229 HIV-infected and 5 (4.2%) of 
119 HIV-uninfected participants. The incidence of laborato-
ry-confirmed influenza-associated ILI per 1000 PY was 46.0 
(95% CI, 30.8–68.6) in HIV-infected and 14.5 (6.0–34.7) in 
HIV-uninfected adults (IRR, 3.21; 95% CI, 1.22–8.41) (Table 2).
In the univariable analysis, history of previous pneu-
monia, household crowding, lower education level, un-
employment, and food insecurity were associated with 
influenza-related ILI (Table 2). After adjustment for age, sex, 
household crowding and food security, HIV-infected adults 
Screened (n = 655)
Eligible (n = 619)
Ineligible (n = 36)
Declined consent (n = 11)
Enrolled (n = 608)
ILI episodes
(n = 348)
Influenza PCR
positive
(n = 29)
HIV infected
n = 360
n = 229
(130 participants)
n = 24
(10.5%)
n = 119
(78 participants)
n = 5
(4.2%)
520 PYFU 348 PYFU
Exited study
10 Died
11 Withdrew
36 Moved away
14 Lost to follow-up
n = 71 (20%)
1 Died
13 Withdrew
25 Moved away
11 Lost to follow-up
HIV uninfected
n = 248
Exited study
n = 46 (19%)
Figure 3. Recruitment and progress of cohort participants. Flow diagram for recruitment, loss to follow-up, and influenza-like illness events among cohort participants. 
Reasons for ineligibility included intention to relocate out of Blantyre (n = 10), inability to attend regular study visits (n = 6), inability to give written informed consent (n = 1), 
evidence of active acute respiratory disease at enrollment (n = 17), and enrollment of another household member in the study (n = 2). Reasons for declining consent included 
not having time (n = 3), not interested (n = 2), fear of participation (n = 4), and wished to seek spouse’s consent (n = 2). Abbreviations: HIV, human immunodeficiency virus; ILI, 
influenzalike illness; PCR, polymerase chain reaction; PYFU, person-years follow-up.
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Table 1. Demographic, Clinical, Household, and Socioeconomic Characteristics of the Cohort Participants
Characteristic
Participants, No./Total (%)a
P Value for DifferencebHIV Infected (n = 360) HIV Uninfected (n = 248)
Male sex 113/360 (31) 111/248 (45) .001
Age, median (IQR), y 37 (31–45) 31 (25–39) <.001c
Medical history
 Asthma 18/360 (5) 8/248 (3) .29
 Chronic lung disease 1/360 (0.3) 0/248 (0) 1.0
 Chronic cardiac disease 2/360 (0.6) 1/248 (0.4) .80
 Chronic kidney disease 0/360 (0) 0/248 (0) …d
 Chronic liver disease 2/359 (0.6) 0/248 (0) .24
 Pregnant (at enrollment) 4/359 (1) 4/248 (2) .84
 Previous pulmonary tuberculosis 90/359 (25) 6/248 (2) <.001
 Pneumonia in past 5 y 59/358 (16) 13//248 (5) <.001
 Current smoker 11/360 (3) 4/248 (2) .14e
 Drinks alcohol 44/359 (12) 35/248 (14) .47
 Body mass index <18.5 kg/m2 38/346 (11) 17/242 (7) .18
Household and socioeconomic factors
No. of children aged <5 y in household 
 0 219/358 (61) 132/247 (54)
 1 114/358 (32) 83/247 (33)
 ≥2 25/358 (7) 32/247 (13) .03
No. of individuals aged >5 y in household 
 0–2 89/358 (25) 56/247 (23)
 3–4 161/358 (45) 91/247 (37)
 ≥5 108/358 (30) 100/247 (41) .03
Crowding indexf
 <1.5 110/360 (30) 66/248 (27)
 1.5–2.4 144/360 (40) 95/248 (38)
 >2.5 106/360 (30) 87/248 (35) .33
Sanitation facility
 None/non-VIP toilet 327/359 (91) 205/248 (83)
 VIP toilet/flush toilet 32/359 (9) 43/248 (17) .002
Water supply
 River/stream/borehole 75/354 (21) 44/246 (18)
 Public tap/standpipe 212/354 (60) 131/246 (53)
 Piped to dwelling 67/354 (19) 71/246 (29) .02
Principal cooking fuel/energy source
 Firewood 77/357 (22) 44/246 (18)
 Charcoal 244/357 (68) 131246 (53)
 Electricity 36/357 (10) 71/246 (29) .66
Highest level of education
 Never attended school 18/359 (5) 10/248 (4)
 Primary 152/359 (42) 89/248 (36)
 Secondary/tertiary 189/359 (53) 149/248 (60) .19
Unemployed 87/359 (24) 47/248 (19) .13
Assets ownedg
 1–2 141/360 (39) 83/248 (33)
 3 151/360 (42) 113/248 (46)
 4–5 68/360 (19) 52/248 (21) .36
Difficulties obtaining food
 Never 137/356 (38) 133/247 (54)
 1–2 times/mo 149/356 (42) 86/247 (35)
 >2 times/mo 70/356 (20) 28/247 (11) <.001
Abbreviations: HIV, human immunodeficiency virus; IQR, interquartile range; VIP, ventilated improved pit latrine.
aData represent No./total (%) of participants unless otherwise specified.
bDetermined with Mantel-Haenszel χ2 test unless stated otherwise.
cWilcoxon rank sum test.
dFor Chronic kidney disease: Chi-square or Fisher’s exact test not possible when neither group has the exposure of interest.
eFisher exact test.
fThe crowding index was calculated as the number of persons in the household divided by the number of sleeping rooms.
gNumber of the following assets owned in household: working refrigerator, radio, mobile phone, bed, and car or motorbike.
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had an approximately 3-fold increased rate of influenza-as-
sociated ILI compared with HIV-uninfected adults (adjusted 
IRR [aIRR], 2.75; 95% CI, 1.02–7.44; Pearson’s goodness-of-
fit test, P = .12).
Among HIV-infected participants, individuals with enrollment 
CD4+ cell counts <200/µL had a higher incidence of influenza-asso-
ciated ILI than those with counts >200/µL, but the association was 
nonsignificant (79.1 vs 40.5 per 1000 PY; IRR, 1.95; 95% CI, .78–
4.92). The effect of HIV on influenza did not differ by ART status.
Other Risk Factors for Influenza Infection
A household crowding index (number of persons in the house-
hold divided by the number of sleeping rooms) of 1.5–2.4 was 
associated with a 3-fold increased risk of influenza-associated ILI, 
compared with households with <1.5 persons per sleeping room 
(aIRR, 3.41; 95% CI, 1.12–10.36). The increased risk was not 
observed in participants who lived in household with a crowding 
index >2.5 (2.06; .62–6.83) (Table 2). Participants who reported 
difficulties accessing food more than twice per month had a 3-fold 
Table 2. Risk Factors for Laboratory-confirmed Influenza Illness Among Cohort Participants
Characteristic
Incidence Rate per 1000 PY of 
Follow-up (95% CI)
Univariable Analysisa Multivariable Analysisa,b
IRR (95% CI) P Value IRR (95% CI) P Value
Sex
 Male 31.4 (16.9–58.3) 1 … 1 …
 Female 34.6 (22.1–54.2) 1.21 (0.52–2.84) .66 0.88 (0.40–1.93) .74
Age group, y
 18–29 20.9 (8.7–50.2) 1 … 1 …
 30–39 39.9 (23.2–68.7) 1.73 (0.60–4.97) … 1.55 (0.54–4.43) …
  ≥40 36.3 (20.1–65.6) 1.33 (0.43–4.05) .30 1.42 (0.47–4.28) .70
HIV status
 Uninfected 14.5 (6.0–34.7) 1 … 1 …
 Infected 46.0 (30.8–68.6) 3.21 (1.22–8.41) .02 2.75 (1.02–7.44) .03
Medical history
 Previous pulmonary tuberculosis 28.2 (23.3–51.1) 0.82 (0.28–2.43) .87 … …
 Pneumonia in past 5 y 54.3 (24.4–120.9) 1.86 (0.75–4.57) .14 … …
 Body mass index <18.5 kg/m2 40.3 (13.0–125.0) 0.81 (0.25–2.68) .73 … …
Housing characteristics
 No. of children aged <5 y in 
household 
… … …
  0 36.2 (22.8–57.5) 1 … …
  1 27.8 (13.9–55.6) 0.77 (0.33–1.77) …
  ≥2 37.3 (12.0–115.5) 1.03 (0.30–3.50) .80 …
 No. of individuals aged ≥5 y in 
household 
… … …
  0–2 25.5 (10.6–61.3) 1 … …
  3–4 28.1 (15.1–52.3) 1.10 (0.38–3.22) … …
  ≥5 44.7 (26.5–75.4) 1.76 (0.63–4.87) .41 …
 Crowding indexc
  <1.5 16.3 (6.12–43.5) 1 … 1 …
  1.5–2.4 47.1 (28.8–76.8) 2.88 (0.96–8.62) … 3.41 (1.12–10.36) …
   ≥2.5 32.0 (16.6–61.5) 1.95 (0.60–6.35) .11 2.06 (0.62–6.83) .06
Socioeconomic characteristics
 Highest level of education … … …
  Never attended/primary 47.6 (30.0–75.6) 1 … …
  Secondary/tertiary 22.5 (12.5–40.7) 0.47 (0.22–1.00) .05 …
 Employment … … …
  No 49.6 (28.8–85.4) 1 … …
  Yes 26.4 (16.2–43.1) 0.53 (0.26–1.11) .09 …
 Food security: difficulty obtaining food
  Never 25.9 (13.9–48.2) 1 … 1 …
  1–2 times/mo 20.7 (9.9–43.5) 0.80 (0.30–2.10) … 0.71 (0.27–1.88) …
  >2 times/mo 87.2 (49.5–153.6) 3.35 (1.45–7.76) .005 3.09 (1.30–7.36) .006
Abbreviations: CI, confidence interval; HIV, human immunodeficiency virus; IRR, incidence rate ratio; PY, person-years.
aIRRs estimated for the incidence of laboratory-confirmed influenza, using Poisson regression.
bAdjusted for sex, age group, HIV status, crowding index, and food security.
cThe crowding index was calculated as the number of persons in the household divided by the number of sleeping rooms.
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increased risk of influenza-associated ILI, compared with those 
with no food access difficulties (aIRR, 3.09; 95% CI, 1.30–7.36). 
Food insecurity was also a possible effect modifier of the impact 
of HIV infection on influenza (P = .01). Among those with fre-
quent difficulty obtaining food, HIV infection was associated with 
10-fold increased incidence of influenza-associated ILI (IRR, 9.50; 
95% CI, 1.27–70.99), but no association was evident in those with 
little or no food insecurity (IRR, 1.18; 95% CI, .32–4.39). No inter-
action was demonstrated with the other covariates.
Case-Control Study: Patient Characteristics
A total of 1645 patients were assessed for eligibility for hospital-
ized LRTI and 846 for ILI, with subsequent recruitment of 518 
and 642 patients, respectively (Figure  4). Patients with severe 
respiratory presentation were older (median age, 35 vs 32 years; 
P < .001), predominantly male (62% vs 43%; P < .001), and had 
a substantially higher prevalence of HIV infection (77% vs 30%; 
P < .001) (Table 3). They also had a higher prevalence of previous 
pulmonary tuberculosis (18% vs 7%), pneumonia within the past 
5 years (22% vs 7%), smoking (11% vs 6%), and regular alcohol 
intake (26% vs 12%) (all P < .001). Sanitation facility, water sup-
ply, cooking fuel, asset ownership, education level, and food se-
curity were also worse among patients with hospitalized LRTI.
Contribution of Influenza to Mild and Severe Respiratory Infection
Influenza was identified in 56 (10.8%) patients with hospitalized 
LRTI (case patients) and 88 (13.7%) patients with ILI (controls) 
(Table 4). Influenza A virus was detected in 30 (53.6%) of the 
case patients and 35 (39.8%) of the controls; all had influenza 
A(H3N2) except 1 control (unsubtyped). Two controls were 
positive for both influenza A(H3N2) and B. Influenza A(H1N1)
pdm09 was not detected during the study period.
Risk Factors for Severe Influenza Presentation
Among the 56 case patients and 88 controls, no difference in 
age and sex was observed (Table 4). Thirty nine (69.6%) of the 
case patients and 26 (29.6%) of the controls were HIV-infected 
(P < .001). Compared with HIV-infected controls, HIV-infected 
case patients had more advanced immunosuppression (median 
CD4+ cell count, 140/µL vs 265/µL; P = .03) and were more likely 
to be receiving ART (35.7 vs 9.1%; P < .001). Case patients were 
more likely to have a low body mass index and report a history 
of tuberculosis and pneumonia. Controls had better sanitation, 
education, and food security. However, household exposure to 
children <5 years old or crowding did not differ according to 
case-control status.
In the univariable analysis, HIV infection, reported history 
of tuberculosis, pneumonia within past 5 years, low body mass 
index (<18.5 kg/m2), month of recruitment, type of water supply, 
sanitation facility, lower education level, and food insecurity were 
associated with being a case patient (Table 4). Month of recruit-
ment was included in the multivariable model a priori owing to 
seasonal discrepancy in the recruitment of patients with hospi-
talized LRTI or ILI. In the multivariable model, HIV infection 
was strongly associated with severe influenza (adjusted OR, 4.98; 
95% CI, 2.09–11.88; P < .001). In addition, reported pneumonia 
Hospitalized LRTI ILI
Screened for eligibility
(n = 1645)
Ineligible (n = 1109)
Declined consent (n = 16)
Reason for refusal:
- 7 not interested
Declined consent (n = 12)
- 5 fear of participation
- 1 no time
- 3 reason not documented
Reason for refusal:
- 3 not interested
- 1 fear of participation
- 6 too unwell
- 2 no time
Ineligible (n = 192)
25 Age <18 y
243 Absence of fever
9 Lack of relevant symptoms
396 Lack of focal chest signs
33 Inability to provide consent
14 Terminal illness
49 Current tuberculosis treatment
488 Illness duration >14 d
18 Age <18 y
69 Absence of fever
96 Illness duration >7 d
10 Required admission
6 Current tuberculosis treatment
3 Terminal illness
9 Hospitalization within 4 wk
10
-
-
-
-
-
- Prior participation67 Hospitalization in past 4 wk
28 Suspected meningitis
13 Prior participation
4 No nasopharyngeal specimen
Screened for eligibility
(n = 846)
Eligible patients
(n = 534)
Eligible patients
(n = 654)
Hospitalized LRTI
recruited
(n = 518)
ILI recruited
(n = 642)
Figure 4. Case-control study recruitment. Abbreviations: ILI, influenza-like illness; LRTI, lower respiratory tract infection.
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Table 3. Demographic, Clinical, Household, and Socioeconomic Characteristics of Adults Enrolled With Hospitalized Lower Respiratory Tract Infection 
and Mild Influenza-like Illness
Characteristic
Participants, No./Total (%)a
P Value for DifferencebHospitalized LRTI (n = 518) ILI (n = 642)
Male sex 323/518 (62) 273/642 (43) <.001
Age, median (IQR), y 35 (30–42) 32 (25–43) <.001c
Prior treatment
 Attended another health facilityd 312/513 (61) 62/635 (10) <.001
 Antibiotics within 2 wke 309/509 (61) 70/630 (11) <.001
 Antimalarials within 2 wk 83/511 (16) 13/630 (2) <.001
HIV status
 HIV infected 396/517 (77) 192/640 (30) <.001
  CD4+ cell count, median (IQR) cells/µL 101 (46–196) 313 (167–450) <.001c
  Receiving ART at enrollmentf 188/233 (81) 68/87 (78) .62
Medical history
 Chronic lung disease 18/503 (4) 15/635 (2) .23
 Chronic cardiac disease 2/503 (0.4) 1/635 (0.2) .59g
 Hypertension 9/503 (2) 19/635 (3) .19
 Chronic kidney disease 1/503 (0.2) 0/503 (0) .44g
 Chronic liver disease 1/503 (0.2) 0/503 (0) .44g
 Pregnant 2/195 (0) 10/369 (3) .19g
 Previous pulmonary tuberculosis 90/514 (18) 45/638 (7) <.001
 Pneumonia in past 5 y 113/512 (22) 46/638 (7) <.001
 Body mass index <18.5 kg/m2 147/495 (30) 67/638 (11) <.001
 Current smoker 58/513 (11) 39/638 (6) <.001
 Drinks alcohol 135/512 (26) 78/638 (12) <.001
Household and socioeconomic factors
 No. of children aged <5 y in household 
  0 296/513 (58) 381/638 (60)
  1 156/513 (30) 195/638 (30)
  ≥2 61/513 (12) 62/638 (10) .48
 Crowding indexh
  <1.5 174/497 (35) 219/612 (36)
  1.5–2.4 203/497 (41) 258/612 (42)
  ≥2.5 120/497 (24) 135/612 (22) .71
 Sanitation facility
  None/non-VIP toilet 284/514 (55) 260/637 (41)
  VIP toilet 188/514 (37) 252/637 (39)
  Flush toilet 42/514 (8) 125/637 (20) <.001
 Water supply
  River/stream/borehole 150/514 (29) 134/638 (21)
  Public tap/standpipe 272/514 (53) 308/638 (48)
  Piped to dwelling 92/514 (18) 196/638 (31) <.001
 Principal cooking fuel/energy source
  Firewood 140/514 (27) 129/637 (20)
  Charcoal 325/514 (63) 421/637 (66)
  Electricity 49/514 (10) 87/637 (14) .006
 Highest level of education
  Never attended school 49/508 (10) 52/638 (8)
  Primary 274/508 (54) 266/638 (42)
  Secondary/tertiary 185/508 (36) 320/638 (50) <.001
 Unemployed 68/514 (13) 91/638 (14) .61
 Assets ownedi
  0 84/515 (16) 75/638 (12)
  1 106/515 (20) 112/638 (18)
  2 122/515 (24) 165/638 (26)
  3 158/515 (31) 206/638 (32)
  4–5 35/515 (9) 80/638 (12) .04
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within 5 years (adjusted OR, 6.49; 95% CI, 2.00–21.07; P < .001), 
poor sanitation facility (3.14; 1.25–7.84; P = .01); and frequent 
difficulty accessing food (20.85; 1.97–221.16; P = .01) were inde-
pendent risk factors for severe influenza.
In a subgroup analysis of HIV-infected case patients and 
controls, there was a trend toward lower CD4+ cell counts in 
case patients (OR, 2.72; 95% CI, .97–7.60; CD4+ cell count, 
<200/µL vs >200/µL). No association was found between ART 
status and influenza severity.
Population-Attributable Fraction
The highest proportions of hospitalized influenza cases were 
attributed to HIV infection (adjusted population-attributable 
fraction, 56.7%; 95% CI, 42.3–67.4) and poor sanitation (40.9%; 
20.5–56.0) (Table 5). Frequent difficulty accessing food accounted 
for 12% (95% CI, 10.6–13.6) of hospitalized influenza cases.
DISCUSSION
In this urban African adult population, HIV infection is an im-
portant risk factor for both symptomatic influenza and severe 
illness. Compared with HIV-uninfected adults, HIV-infected 
adults had a 3 times higher incidence of influenza-associ-
ated ILI, and a 5-fold greater odds of severe influenza disease. 
Furthermore, nearly 60% of influenza-related hospitalized LRTI 
cases were attributable to HIV. Although neither study was 
powered to examine the effect of HIV at different levels of im-
munosuppression, our data suggest higher incidence and greater 
disease severity among those with CD4+ cell counts <200/µL.
Previous population-level surveillance and retrospective 
studies in South Africa and Kenya that have examined the 
association between HIV and influenza found a higher disease 
burden [8–10] and an increased risk of influenza-associated 
hospitalization in HIV-infected persons [11–13], particular 
among those with severe immunosuppression [13]. The cur-
rent studies provide robust evidence to support these findings 
having prospectively ascertained HIV status, CD4+ cell count, 
and information on ART, as well as other exposures, including 
household and socioeconomic characteristics that may con-
found the association between HIV and influenza.
We found a higher incidence of influenza-associated ILI 
among HIV-infected than among HIV-uninfected individuals. 
Although this could indicate an increased susceptibility to in-
fection, it may instead, or also, reflect a greater propensity of 
HIV-infected individuals to develop symptomatic illness after 
influenza infection, which has been described elsewhere [23]. 
This is a pertinent finding in high–HIV prevalence settings, be-
cause HIV-infected individuals may play an important role in 
the community transmission of influenza.
Taken together, data from the 2 studies present a persuasive 
argument for a strong association between HIV and influenza. 
The finding that more than half of hospitalized influenza pres-
entations in Malawian adults were attributable to HIV further 
emphasizes its critical role in severe influenza in this population. 
Because pneumonia is the most common cause of adult medical 
admissions at QECH [24], effective influenza preventive strate-
gies could substantially reduce the burden of acute respiratory 
infections in Malawi and other similar resource-limited settings.
Inactivated influenza vaccines have demonstrated safety and 
efficacy in HIV-infected persons [25]. Clinical efficacy of 75.5% 
has been reported in South African HIV-infected adults, but 
Characteristic
Participants, No./Total (%)a
P Value for DifferencebHospitalized LRTI (n = 518) ILI (n = 642)
 Difficulties obtaining food
  Never 247/514 (48) 367/638 (58)
  1–2 times/mo 226/514 (44) 250/638 (39)
  >2 times/mo 41/514 (8) 31/638 (3) <.001
Season of recruitment
 January–March 99/518 (19) 204/642 (32)
 April–June 100/518 (19) 180/642 (28)
 July–September 161/518 (31) 145/642 (24)
 October–December 15/518 (31) 102/642 (16) <.001
Abbreviations: ART, antiretroviral treatment; HIV, human immunodeficiency virus; ILI, influenzalike illness; IQR, interquartile range; LRTI, lower respiratory tract infection, VIP, ventilated 
improved pit latrine.
aData represent No./total (%) unless otherwise specified. 
bDetermined with Mantel-Haenszel χ2 test unless stated otherwise.
cWilcoxon rank sum test.
dIncluding attendance at another hospital, health center, private clinic, traditional healer, or pharmacy. 
eExcluding cotrimoxazole prophylaxis in HIV-infected individuals.
fDenominator is the number of patients with known HIV infection at enrollment.
gFisher exact test.
hThe crowding index was calculated by the number of persons in the household divided by the number of sleeping rooms.
iNumber of the following assets owned in household: working refrigerator, radio, mobile phone, bed, and car/motorbike.
Table 3. Continued
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Table 5. Population-Attributable Fraction of Modifiable Risk Factors for Severe Influenza
Risk Factor
Proportion of Case  
Patients Exposed, % Adjusted OR (95% CI) P Value
Adjusted Population-Attributable 
Fraction (95% CI), %
HIV infection 70 4.98 (2.09–11.88) <.001 56.7 (42.3–67.4)
Sanitation facility
 None/non-VIP toilet 39 3.14 (1.25–7.84) .01 40.9 (20.5–56.0)
 VIP/flush toilet 61 1
Difficulties obtaining food
 Never 50 1 …
 1–2 times/wk 38 1.15 (0.47–2.84) 6 (−40.9 to 38.0)
 >2 times/wk 12 20.85 (1.97–221.16) .01 12.0 (10.3–13.7)
Abbreviations: CI, confidence interval; HIV, human immunodeficiency virus; OR, odds ratio; VIP, ventilated improved pit latrine.
Table 4. Risk Factors for Severe Influenza Presentation in Influenza-Positive Case Patients and Controls
Characteristic
Participants, No./Total (%) Univariable Analysisc Multivariable Analysisc,d
Case Patients (n = 56)a Controls (n = 88)b OR (95% CI) P Value OR (95% CI) P Value
Male sex 28/56 (50) 43/88 (49) 0.96 (0.49–1.88) .89 … …
Age group, y … … …
 18–29 17/56 (30) 36/88 (41) 0.75 (0.32–1.73) .32 …
 30–39 22/56 (39) 25/88 (28) 1.40 (0.61–3.22) … …
  ≥40 17/56 (30) 27/88 (31) 1 … …
HIV infected 39/56 (70) 26/88 (30) 5.47 (2.63–11.36) <.001 4.98 (2.09–11.88) <.001
Medical history …
 Previous pulmonary tuberculosis 10/56 (18) 5/88 (6) 3.61 (1.16–11.20) .03 … …
 Pneumonia in past 5 y 17/55 (31) 7/88 (8) 5.18 (1.98–13.53) .001 6.49 (1.95–21.25) .001
 Body mass index <18.5 kg/m2 12/53 (23) 9/88 (10) 2.57 (1.00–6.60) .05 …
Housing and socioeconomic 
characteristics
 Sanitation facility
  None/non-VIP toilet 34/55 (61) 37/88 (42) 2.12 (1.08–4.22) .03 3.14 (1.25–7.84) .01
  VIP toilet/flush toilet 22/55 (40) 51/88 (58) 1 … 1 …
 Water supply … … …
  River/stream/borehole 15/56 (27) 19/88 (22) 2.54 (0.93–6.98) .07 …
  Public tap/standpipe 32/56 (57) 40/88 (45) 2.58 (1.07–6.22) … …
  Piped to dwelling 9/56 (16) 29/88 (33) 1 … …
 Highest level of education … … …
  Never attended 5/55 (9) 15/88 (17) 1 … …
  Primary 34/55 (62) 28/88 (32) 3.64 (1.18–11.27) … …
  Secondary/tertiary 16/55 (29) 45/88 (51) 1.07 (0.33–3.41) .002 …
 Difficulties obtaining food
  Never 28/56 (50) 58/88 (66) 1 … 1 …
  1–2 times/mo 21/56 (38) 29/88 (33) 1.50 (0.73–3.08) … 1.15 (0.47–2.84) …
  >2 times/mo 7/56 (12) 1/88 (1) 14.4 (1.70–123.65) .007 20.85 (1.97–221.16) .01
Month of recruitment
 January–March 16/56 (29) 49/88 (56) 1 … 1 …
 April–June 15/56 (27) 18/88 (20) 2.55 (1.05–5.20) … 3.36 (1.13–9.95) …
 July–September 12/56 (21) 9/88 (10) 4.08 (1.45–11.46) … 6.34 (1.69–23.80) …
 October–December 13/56 (23) 12/88 (14) 3.32 (1.25–8.72) .01 3.60 (1.07–12.10) .01
Abbreviations: CI, confidence interval; HIV, human immunodeficiency virus; OR, odds ratio; PCR, polymerase chain reaction; VIP, ventilated improved pit latrine.
aCase had severe (hospitalized) lower respiratory tract infection and a positive PCR result for influenza.
bControls had influenza-like illness and a positive PCR result for influenza.
cUnconditional logistic regression.
dAdjusted for HIV status, history of pneumonia within 5 years, month of recruitment, sanitation facility, and food security.
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the trial excluded patients with comorbid conditions and ART-
naive patients with CD4+ cell counts <100/μL [26]. Influenza 
vaccines are not widely deployed in most African countries [2, 
27]. Before consideration of HIV-infected persons as a target 
group for immunization, policy makers will require evidence 
of vaccine efficacy in the context of advanced immunosup-
pression and/or comorbid conditions, as well as the potential 
public health impact and cost-effectiveness of vaccinating HIV-
infected individuals, compared with other target groups (eg, 
pregnant women, young children). The acceptability of annual 
vaccination, feasibility of vaccine administration at ART clinics, 
and optimal timing of vaccination in the absence of clear sea-
sonality will require elucidation. Numerous regulatory, logisti-
cal, and financial obstacles will need to be overcome if targeted 
influenza vaccination policies are to be successfully and sustain-
ably implemented in the region.
The introduction of ART was associated with a dramatic de-
cline in influenza-attributable hospitalizations in the United 
States [28], and improved survival after pandemic influenza 
A(H1N1) infection in Mexico [29]. However, this beneficial 
effect has not been observed in Africa. Cohen et al [30] found 
no difference in case fatality ratio by ART status among HIV-
infected individuals with influenza-positive severe acute re-
spiratory illness [30]. A  Malawian study demonstrated poor 
reconstitution of influenza-specific CD4+ T-cell response in 
HIV-infected adults after 12 months of highly active ART, des-
pite a rise in CD4+ cell count [31]. Hence the impact of ART on 
the relationship between HIV and influenza severity requires 
further evaluation.
Identification of household crowding, poor sanitation, and 
food insecurity as risk factors for influenza highlight the im-
portance of current public health interventions to alleviate 
hunger and poverty and improve access to clean water and sani-
tation [32]. Food insecurity emerged as a previously unrecog-
nized risk factor for both influenza illness and severity. More 
in-depth evaluation of food insecurity and its association with 
influenza and other respiratory infections is warranted [33].
Our results, along with other data from the region, contrast 
with those from developed settings [6]. This highlights the lim-
itations of extrapolating findings from developed settings to 
inform influenza control policies in Africa. Differences in the 
observed impact of HIV on influenza burden and severity may 
be due to more advanced immunosuppression, poorer access to 
ART, higher prevalence of comorbid conditions, poverty-related 
factors identified in this study, compared with other regions.
Our study has several limitations. First, it was conducted in 
a single urban center, which may limit the generalizability of 
our findings to rural populations. Second, this study was not 
powered to assess the impact of CD4+ cell count or ART on 
influenza incidence and severity. CD4+ cell counts were meas-
ured during acute illness in the case-control study; the degree of 
immunosuppression may not be accurately represented because 
CD4+ cell count depression can occur during acute illness. 
Third, passive surveillance was used for case ascertainment in 
both studies; underascertainment of ILI episodes, and therefore 
influenza cases, is conceivable. Biased estimates away from the 
null could have resulted if HIV-infected cohort participants 
were more likely than uninfected individuals to present with ILI 
. Similar bias could have arisen if HIV-infected individuals had 
a higher propensity to attend hospitals with severe respiratory 
symptoms in the case-control study. However, there was no sig-
nificant difference in the incidence of ILI between HIV-infected 
and uninfected cohorts, and a greater proportion of HIV-related 
ILI cases had severe clinical signs (Supplementary Table S1). 
Furthermore, the majority of case-control study participants 
were unaware of their HIV status at enrollment. Finally, we were 
unable to control for bacterial coinfection in the case-control 
study, because diagnostic tests for bacteria were undertaken in 
case patients but not controls.
We have comprehensively evaluated the association between HIV 
and influenza, identifying HIV-infected persons at particular risk 
of symptomatic influenza and severe disease. Influenza-preventive 
strategies should be an important aspect of the management of 
HIV-infected adults in sub-Saharan Africa. Further studies are 
needed in Malawi and other high–HIV prevalence settings to deter-
mine influenza vaccine efficacy in persons with advanced immuno-
suppression and evaluate the potential public health impact ahead 
of operational research addressing the logistical barriers to imple-
menting large-scale vaccination programs.
Supplementary Data
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Consisting of data provided by the authors to benefit the reader, the posted 
materials are not copyedited and are the sole responsibility of the authors, 
so questions or comments should be addressed to the corresponding author.
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